The Food and Drug Administration (FDA) has delayed its decision on the marketing application of drugmaker Orexigen Therapeutics Inc over its obesity drug, Contrave. The application has been delayed by three months. This move has badly affected the company's shares as it was recorded down as much as 20 percent on Wednesday. Contrave is a combination of the antidepressant bupropion and … [Read more...]
You are here: Home / Archives for Contrave